ReviewExpert review of vaccines2016
Molecular mechanisms for enhanced DNA vaccine immunogenicity.
Review in Expert review of vaccines, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04934111 (A Clinical Trial to Assess the Safety and Immunogenicity of LNP-nCOV saRNA-02, a Self-amplifying Ribonucleic Acid), which is not on this map. Cited by 179 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Clinical Trial to Assess the Safety and Immunogenicity of LNP-nCOV saRNA-02, a Self-amplifying Ribonucleic Acid (saRNA) Vaccine, in SARS-CoV-2 Seronegative and Seropositive Uganda Population
Who cites it
179 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Controlling timing and location in vaccines.Advanced drug delivery reviews · 2020Pooled it
- Safety and Immunogenicity of an Andes Virus DNA Vaccine by Needle-Free Injection: A Randomized, Controlled Phase 1 Study.The Journal of infectious diseases · 2024Trial
- DNA-based vaccines: Advances, applications, and future prospects.Genes & diseases · 2026Review
- Rickettsial Diseases and Vaccines: Is There an Opportunity for Plant-Made Vaccine Technology?Biotechnology and bioengineering · 2026Review
- Plasmid-DNA EncodedPharmaceutics · 2026Article
- Microneedles for Vaccination: Mechanistic Foundations, Materials Innovation, Clinical Translation, and Global Health Implementation.Pharmaceutics · 2026Review
- Trivalent AMH-INH-RFRP DNA Vaccine Enhances Estrus and Ovulation Rates in Buffaloes.Animals : an open access journal from MDPI · 2026Article
- Beyond Antibiotics: Alternative Strategies TargetingExpert reviews in molecular medicine · 2026Review
- Next-generation mucosal vaccines for respiratory viruses: Immunological correlates, platform design and clinical translation.World journal of virology · 2026Review
- Article
- Development and Immunogenicity Assessment of a Multi-Epitope Antigen Against Zika Virus: An In Silico and In Vivo Approach.Vaccines · 2025Article
- Cancer Vaccines: Molecular Mechanisms, Clinical Progress, and Combination Immunotherapies with a Focus on Hepatocellular Carcinoma.Current issues in molecular biology · 2025Review
- Comment on: A single dose recombinant AAV based CHIKV vaccine elicits robust and durable protective antibody responses in mice.PLoS neglected tropical diseases · 2025Article
- Article
- DNA Vaccines in the Post-mRNA Era: Engineering, Applications, and Emerging Innovations.International journal of molecular sciences · 2025Review
- Research on inner membrane complex protein 1: a novel nanovaccines against Toxoplasma gondii.BMC veterinary research · 2025Article
- Decoy DNA Protects Molecular Tension Probes from DNase Degradation.Angewandte Chemie (International ed. in English) · 2025Article
- Immunogenicity of DNA, mRNA and Subunit Vaccines Against Beak and Feather Disease Virus.Vaccines · 2025Article
- Innovation in mRNA Vaccines and RNAi via Protein Nanocages.Vaccines · 2025Review
- Efficient Delivery of SARS-CoV-2 Plasmid DNA in HEK-293T Cells Using Chitosan Nanoparticles.Pharmaceuticals (Basel, Switzerland) · 2025Article
119 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In the two decades since their initial discovery, DNA vaccines technologies have come a long way. Unfortunately, when applied to human subjects inadequate immunogenicity is still the biggest challenge for practical DNA vaccine use. Many different strategies have been tested in preclinical models to address this problem, including novel plasmid vectors and codon optimization to enhance antigen expression, new gene transfection systems or electroporation to increase delivery efficiency, protein or live virus vector boosting regimens to maximise immune stimulation, and formulation of DNA vaccines with traditional or molecular adjuvants. Better understanding of the mechanisms of action of DNA vaccines has also enabled better use of the intrinsic host response to DNA to improve vaccine immunogenicity. This review summarizes recent advances in DNA vaccine technologies and related intracellular events and how these might impact on future directions of DNA vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.